Literature DB >> 17083038

Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.

Elizabeth Sinclair1, Qi Xuan Tan, Margaret Sharp, Valerie Girling, Chungkee Poon, Mark Van Natta, Douglas A Jabs, Margaret Inokuma, Holden T Maecker, Barry Bredt, Mark A Jacobson.   

Abstract

To determine potential correlates of immune recovery from AIDS-related cytomegalovirus retinitis (CMVR), multiparameter flow cytometry was used to characterize CMV-specific T cells from subjects with CMVR. Individuals with active retinitis were compared with those who had been clinically immunorestored by antiretroviral therapy and had > or =2 years of ophthalmologic follow-up without anti-CMV therapy or retinitis reactivation or progression. In comparison with patients with active retinitis, immunorestored patients had higher circulating CD4(+) and CD8(+) T cells expressing interleukin-2 and interferon- gamma in response to combined CMV pp65 and IE1 peptide pool stimulation. CD4(+) T cell responses were predominantly to pp65, whereas CD8(+) T cell responses were predominantly to IE. Immunorestored patients, compared with patients with active retinitis, had increased levels of circulating CMV-specific CD8(+) T cells with "early" (CD27(+)CD28(+)CD45RA(+), CD27(+)CD28(+)CD45RA(-)) and "intermediate" (CD27(-)CD28(+)CD45RA(-)) phenotypes. Recovery from AIDS-related CMVR after the initiation of antiretroviral therapy may be mediated by CMV-specific CD4(+) and CD8(+) T cells capable of promoting antigen-specific CD8(+) T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083038     DOI: 10.1086/508997

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.

Authors:  Peter A Gillis; Nelmary Hernandez-Alvarado; Josephine S Gnanandarajah; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2014-05-20       Impact factor: 3.641

2.  Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Authors:  Danilo R Casimiro; Kara Cox; Aimin Tang; Kara J Sykes; Meizhen Feng; Fubao Wang; Andrew Bett; William A Schleif; Xiaoping Liang; Jessica Flynn; Timothy W Tobery; Keith Wilson; Adam Finnefrock; Lingyi Huang; Salvatore Vitelli; Jing Lin; Deepa Patel; Mary-Ellen Davies; Gwendolyn J Heidecker; Daniel C Freed; Sheri Dubey; David H O'Connor; David I Watkins; Zhi-Qiang Zhang; John W Shiver
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

3.  Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis.

Authors:  Shiney Seo; Corey Smith; Christopher Fraser; Rajan Patheja; Shaheen P Shah; Sweera Rehan; Pauline Crooks; Michelle A Neller; Rajiv Khanna
Journal:  Blood Adv       Date:  2019-06-11

4.  Physical function impairment of older, HIV-infected adults is associated with cytomegalovirus immunoglobulin response.

Authors:  Kristine M Erlandson; Amanda A Allshouse; Eric Rapaport; Brent E Palmer; Cara C Wilson; Adriana Weinberg; Samantha MaWhinney; Thomas B Campbell
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-08       Impact factor: 2.205

5.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Authors:  Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

6.  In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits.

Authors:  A Weinberg; J Spritzler; M Nokta; R Schrier; A Landay; D Brown; R Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

7.  A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Authors:  Hiroyu Hatano; Rebecca Scherzer; Yuaner Wu; Kara Harvill; Kristinalisa Maka; Rebecca Hoh; Elizabeth Sinclair; Sarah Palmer; Jeffrey N Martin; Michael P Busch; Steven G Deeks; Priscilla Y Hsue
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

8.  DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.

Authors:  Kara S Cox; James H Clair; Michael T Prokop; Kara J Sykes; Sheri A Dubey; John W Shiver; Michael N Robertson; Danilo R Casimiro
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

9.  Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS.

Authors:  Mark A Jacobson; Qi Xuan Tan; Valerie Girling; C Poon; Mark Van Natta; Douglas A Jabs; Margaret Inokuma; Holden T Maecker; Barry Bredt; Elizabeth Sinclair
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

10.  Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation.

Authors:  Sara Cantisán; Julián Torre-Cisneros; Rosario Lara; Alberto Rodríguez-Benot; Francisco Santos; Juan Gutiérrez-Aroca; Inmaculada Gayoso; Marcelino González-Padilla; Manuel Casal; Antonio Rivero; Rafael Solana
Journal:  Clin Vaccine Immunol       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.